Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Podcasts|November 16, 2026

The Ron Lanton Report: Ossium Health's Bone Marrow Bank

Ossium Health’s Kevin Caldwell joins The Ron Lanton Report to explain how banked, deceased-donor marrow is replacing a months-long search for a living donor with a product hospitals can order on demand.

In this episode of The Ron Lanton Report, Kevin Caldwell, CEO, co-founder, and president of Ossium Health, joins Ron Lanton, senior partner, Lanton, Lanton & Sosa Law PLLC, to describe how his company is rebuilding the bone marrow transplant process around deceased organ donors rather than living volunteers.

In his conversation with Lanton, Caldwell explains that traditional transplants depend on finding, testing, and consenting a living donor, a process that can take months while a patient’s disease progresses, and one that sometimes fails outright if a match becomes unavailable or a patient deteriorates first. Ossium’s alternative draws on the same deceased organ donor population used for solid organ transplants for decades, recovering far more cells per donor than could ever ethically be taken from a living person, then cryopreserving and banking that marrow for on-demand use.

Caldwell frames the company’s work as combining pieces of science that have existed for decades and dramatically improving each one: Ossium’s recovery process yields roughly three times the cells of prior methods with double the sterility success, while cryopreservation techniques developed by Erik Woods, CSO, co-founder & executive vice president, retain more than 90% of cells post-thaw, compared to roughly half lost under older methods. The result is a product that can reach a transplant center in as little as 31 hours, versus a standard of care of 12 to 15 weeks.

Caldwell also details how physician adoption began cautiously in 2023 before accelerating sharply after the first deceased-donor marrow transplant for blood cancer was performed in 2024 at Henry Ford Transplant Center by Dr. Munir Abidi, with strong, swift engraftment and no serious adverse events. The initial planned 12-patient study is now fully enrolled and Ossium is continuing to treat patients under an expanded access program, with transplants happening roughly once per week.

Looking ahead, Caldwell identifies physician education and operational scaling such as scaling from roughly three donors processed per day to a potential 20 domestically and more than 100 globally, as the next hurdles to widespread use. He closes the discussion by emphasizing that Ossium’s ultimate goal is to remove donor availability as a variable entirely, letting physicians and patients make treatment decisions on their own timeline rather than a donor’s.


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.